Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Verona Pharma plc will report its financial results for Q2 2023 on August 3, 2023. An investment community conference call will be held to discuss the results and provide a corporate update.
Positive
Verona Pharma will report its financial results for Q2 2023, which could positively affect the stock price if the results exceed expectations.
07/20/2023 - 02:00 AM
LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and ask to join the Verona Pharma call:
+1-833-816-1396 for callers in the United States +1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com , and the audio replay will be available for 90 days.
For further information please contact:
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first non-steroidal therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company has evaluated nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In the second quarter of 2023, Verona Pharma submitted a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for ensifentrine for the maintenance treatment of patients with COPD. Two additional formulations of ensifentrine have been evaluated in Phase 2 studies for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com .
When will Verona Pharma report its financial results for Q2 2023?
Verona Pharma will report its financial results for Q2 2023 on August 3, 2023.
What will be discussed during the investment community conference call?
The investment community conference call will discuss the financial results for Q2 2023 and provide a corporate update.
How can I participate in the conference call?
To participate in the conference call, dial one of the following numbers: +1-833-816-1396 for callers in the United States or +1-412-317-0489 for international callers.
Where can I find the webcast of the conference call?
The webcast of the conference call will be available on the Events and Presentations link on Verona Pharma's website, www.veronapharma.com.
How long will the audio replay of the conference call be available?
The audio replay of the conference call will be available for 90 days.
VRNA Rankings
#1797 Ranked by Stock Gains
VRNA Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Medicinal and Botanical Manufacturing
Country
United Kingdom
City
3 More London Place
About VRNA
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
